ST. JUDE SURGEON TRAINING FOR TORONTO SPV STENTLESS PORCINE VALVE TO REACH OVER 100 U.S. PHYSICIANS BY YEAR-END, COMPANY SAYS; FDA APPROVES DEVICE NOV. 24
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical hopes to train over 100 U.S. surgeons in the use of the Toronto SPV stentless porcine heart valve by the end of the year. Approved by FDA on Nov. 24 as a replacement for malfunctioning native or prosthetic aortic heart valves, the Toronto SPV is the first stentless tissue heart valve to reach the U.S. market.